ES2112310T3 - Caracterizacion de defectos de la agregacion de plaquetas. - Google Patents

Caracterizacion de defectos de la agregacion de plaquetas.

Info

Publication number
ES2112310T3
ES2112310T3 ES92901259T ES92901259T ES2112310T3 ES 2112310 T3 ES2112310 T3 ES 2112310T3 ES 92901259 T ES92901259 T ES 92901259T ES 92901259 T ES92901259 T ES 92901259T ES 2112310 T3 ES2112310 T3 ES 2112310T3
Authority
ES
Spain
Prior art keywords
defects
characterization
platelet aggregation
union
characterize
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901259T
Other languages
English (en)
Inventor
Mark H Ginsberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2112310T3 publication Critical patent/ES2112310T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Laminated Bodies (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESCRIBEN METODOS PARA CARACTERIZAR DEFECTOS EN LA CONGREGACION DE LAS PLAQUETAS. LOS DEFECTOS SE CARACTERIZAN COMO DEFECTOS DE ACTIVACION, DE UNION O DE POST-OCUPACION. EN UNA CONFORMACION DE LA INVENCION UNA VARIANTE DE CAM DE LA TROMBASTENIA DE GLANZMANN SE CARACTERIZA POR TENER UN DEFECTO DE UNION DE LOS LIGANTES. EN OTRA CONFORMACION, SE IDENTIFICA UN PACIENTE CON MIELOFIBROSIS POR TENER UN DEFECTO DE ACTIVACION. SE PRESENTAN ANALISIS RAPIDOS QUE UTILIZAN LA CITOMETRIA DE FLUJO ACTIVADA POR FLUORESCENCIA. TAMBIEN SE DESCRIBEN EQUIPOS DE DIAGNOSTICO QUE COMPRENDEN ANTICUERPOS ADECUADOS PARA CARACTERIZAR LOS DEFECTOS MENCIONADOS.
ES92901259T 1990-11-15 1991-11-15 Caracterizacion de defectos de la agregacion de plaquetas. Expired - Lifetime ES2112310T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/614,723 US5196309A (en) 1990-11-15 1990-11-15 Characterization of platelet aggregation disorders

Publications (1)

Publication Number Publication Date
ES2112310T3 true ES2112310T3 (es) 1998-04-01

Family

ID=24462455

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92901259T Expired - Lifetime ES2112310T3 (es) 1990-11-15 1991-11-15 Caracterizacion de defectos de la agregacion de plaquetas.

Country Status (13)

Country Link
US (2) US5196309A (es)
EP (1) EP0557451B1 (es)
JP (1) JP3186765B2 (es)
AT (1) ATE163481T1 (es)
AU (1) AU650312B2 (es)
CA (1) CA2096230C (es)
DE (1) DE69128966T2 (es)
DK (1) DK0557451T3 (es)
ES (1) ES2112310T3 (es)
GR (1) GR3026510T3 (es)
IE (1) IE62627B1 (es)
PT (1) PT99532B (es)
WO (1) WO1992008982A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427913A (en) * 1992-12-03 1995-06-27 Alberta Cancer Board Methods for determining platelet function
US5763199A (en) * 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
US5561047A (en) * 1994-12-13 1996-10-01 The Trustees Of The University Of Pennsylvania Method of identifying effectors of integrin activation
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
EP0983509B1 (en) * 1997-05-14 2005-08-17 Biosite Diagnostics Inc. Rapid evaluation of the ratio of biological molecules
AU7581798A (en) * 1997-05-20 1998-12-11 Johns Hopkins University, The A novel thrombopoietin signaling defect in polycythemia vera platelets
FR2764388B1 (fr) * 1997-06-06 1999-08-27 Biocytex Nouvelle methode d'analyse des recepteurs plaquettaires gpiib/iiia
US6210904B1 (en) 1997-10-14 2001-04-03 Merck & Co., Inc. Anticoagulant test
US6040182A (en) * 1997-11-12 2000-03-21 Becton Dickinson And Company Method and materials for efficiency protein immobilization on tissue culture treated assay plates
US6063584A (en) * 1997-11-21 2000-05-16 Merck & Co., Inc. Anticoagulant test
AU2002220255A1 (en) * 2000-12-05 2002-06-18 The Penn State Research Foundation A monoclonal antibody-based diagnostic assay for gamma fibrinogen
US20040131500A1 (en) * 2002-01-18 2004-07-08 Chow Herbert S. Device and method for evaluating platelets
US7790362B2 (en) 2003-07-08 2010-09-07 Accumetrics, Inc. Controlled platelet activation to monitor therapy of ADP antagonists
US20070243632A1 (en) 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
JP2010261790A (ja) * 2009-05-01 2010-11-18 Takemichi Kanazawa 血管障害の素因の検査方法、及び治療法の選択方法
WO2015138916A1 (en) * 2014-03-14 2015-09-17 Yves Claude Nicolau Myo-inositol trispyrophoshate as an anti-diabetic agent
BR112017015133B1 (pt) * 2015-01-14 2022-09-27 Sorin Dinu Dispositivo resistente para o nivelamento da areia até a cota e para a montagem da tubulação no canal de esgoto
CN111033256B (zh) 2017-09-05 2022-07-12 深圳迈瑞生物医疗电子股份有限公司 血小板聚集样本的报警方法、血细胞分析仪及存储介质

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
US4820505A (en) * 1985-04-04 1989-04-11 Scripps Clinic And Research Foundation Detection of activated platelets with antibodies to thrombospondin
US5114842A (en) * 1987-07-08 1992-05-19 The Scripps Research Institute Peptides and antibodies that inhibit platelet adhesion

Also Published As

Publication number Publication date
EP0557451A4 (en) 1994-06-01
GR3026510T3 (en) 1998-07-31
JP3186765B2 (ja) 2001-07-11
DK0557451T3 (da) 1998-09-23
AU650312B2 (en) 1994-06-16
CA2096230A1 (en) 1992-05-16
JPH06504842A (ja) 1994-06-02
EP0557451B1 (en) 1998-02-25
EP0557451A1 (en) 1993-09-01
WO1992008982A1 (en) 1992-05-29
PT99532B (pt) 1999-04-30
DE69128966T2 (de) 1998-06-18
US5196309A (en) 1993-03-23
IE913975A1 (en) 1992-05-20
AU9082491A (en) 1992-06-11
CA2096230C (en) 2003-05-27
IE62627B1 (en) 1995-02-22
ATE163481T1 (de) 1998-03-15
US5656442A (en) 1997-08-12
DE69128966D1 (de) 1998-04-02
PT99532A (pt) 1992-09-30

Similar Documents

Publication Publication Date Title
ES2112310T3 (es) Caracterizacion de defectos de la agregacion de plaquetas.
NO177953C (no) Apparat for fremstilling av et konsentrat av koaguleringsfaktorer, såsom fibrinogen, fra en blodporsjon
SE8504872D0 (sv) Selekteringsforfarande och medel herfor
SE7906148L (sv) Forfarande for framstellning av en biologisk komposition for anvendning sasom referenskontroll vid diagnostiska tester
ATE153701T1 (de) Immunchromatographischer assay und verfahren zur nutzung desselben
DE69112610D1 (de) Sammlung von analyten aus der mundhöhle für immunoassays.
DE60030447D1 (de) Spritzenkit für die konzentration von thrombozyten und verfahren
FI891078A0 (fi) Peptider och antikroppar, som inhiberar plateletadhesion.
ATE40602T1 (de) Immunchemisches messverfahren.
ATE93698T1 (de) Vorrichtung zur entnahme von koerperfluessigkeiten.
FR2594846B1 (fr) Procede de preparation de la serum albumine humaine mature
SE8400587D0 (sv) Sett att bestemma isotransferriner
SE8403630L (sv) Humana proteiner
ES8501630A1 (es) Un metodo para detectar o vigilar el estado de una condicion patologica humana que implica proteina de tejido conjuntivo.
ES2151494T3 (es) Metodo para la preparacion y analisis de leucocitos en sangre completa mediante la utilizacion de citometria de flujo.
AT358592B (de) Verfahren zur herstellung von neuen 4-(n- acetyl)-amino-tetrahydro-1,3,5-triazin-2,6-dion -derivaten
ATE47829T1 (de) 5,9-dimethylheptadecan verfahren und mittel zur bekaempfung der fleckenminiermotte leucoptera scitella.
SU682347A1 (ru) Рабоча среда дл электроэрозионной обработки
FI922710A0 (fi) Eliminering av aktiverade lymfocyter.
DE3886851D1 (de) Stroboskoplicht-Generator für insbesondere medizinische Zwecke.
IT1086463B (it) Densitometro per la determinazione quantitativa di frazioni proteiche separate per via elettroforetica,particolarmente per la diagnosi clinica
ES2028798T3 (es) Procedimiento para la obtencion de hidroxiindolesteres.
EP0453419A3 (en) Use of the sp-2 monoclonal antibody for diagnostics and for monitoring of the hiv infection progress
SU1823619A1 (ru) Способ дифференциальной диагностики туберкулеза и рака легких
FI894503A0 (fi) Immunologisk motverkan foer tumoerer och virus foer diagnostisk anvaendning.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 557451

Country of ref document: ES